Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury through NLRP3 Inflammasome-Mediated Pyroptosis Inhibition via Activating Nrf2

Figure 7

AST IV alleviates CIRI by activating Nrf2. (a) Brain section slices stained with TTC to visualize the ischemic cerebral infarct volume. Scale bar, 10 mm. All rats were randomly assigned to the following groups: the sham group (natural saline, 10 ml/kg), the MCAO/R group (normal saline), and the MCAO/R + AST IV group (AST IV was administered on three successive days at each indicated time, MCAO/R surgery was performed 2 h after the final administration, and AST IV was administered at 24 h just after MCAO/R to achieve reperfusion). (b) Quantitative analysis of brain infarct volume. Values are , . vs. the sham group; ^## vs. the MCAO/R group;^&& vs. the AST IV group. (c) Neurological deficit scores. Values are , . (d) Cell viability was determined with CCK8 assays. Values are , . vs. the sham group; ^## vs. the OGD/R group; ^&, ^&& vs. the AST IV group. (e) LDH leakage rate was assayed using the LDH Cytotoxicity Detection Kit. Values are , .

(a)

(b)

(c)

(d)

(e)